Literature DB >> 24635515

Ten years survey of primary HIV-1 resistance in Serbia: the occurrence of multiclass resistance.

Maja Stanojevic1, Marina Siljic, Dubravka Salemovic, Ivana Pesic-Pavlovic, Sonja Zerjav, Valentina Nikolic, Jovan Ranin, Djordje Jevtovic.   

Abstract

In Serbia, the first cases of HIV infection were reported in 1985, whereas antiretroviral (ARV) therapy has been in use since 1987. With this study we aimed to assess the occurrence and pattern of HIV resistance mutations among newly diagnosed patients in the period 2002-2011. The study prospectively included 181 adult patients. Genotypic HIV-1 drug resistance testing was performed and drug resistance was scored according to the 2009 WHO list for surveillance of drug resistance mutations (SDRMs). A bioinformatic approach was used to estimate the duration of infection by calculating the percentage of ambiguous basecalls per sequence, with a cutoff of 0.47% as the delimiter for recent infection. The overall prevalence of transmitted drug resistance (TDR) found in the study was 8.8% (16/181, 95% CI=5.5-13.8). Thirty-one percent of resistant samples contained multiple SDRMs. In particular, 5/16 patients with resistance carried viral strains with SDRMs to multiple ARV classes, hence one-third of resistant strains were multiclass resistant, including non-B strains. A total of 51.9% of samples (94/181) were classified as recent infection, with a significant increase in the second part of the study period. However, the prevalence of TDR in recent infection was 6.4% (6/94, 95% CI=2.9-13.2), not statistically different from that found in nonrecent infection. We showed a changing pattern of TDR mutations over the study period, with a substantial occurrence of multiclass resistance, across different HIV subtypes. Our results highlight the need for continued surveillance of primary resistance.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 24635515      PMCID: PMC4077010          DOI: 10.1089/AID.2013.0270

Source DB:  PubMed          Journal:  AIDS Res Hum Retroviruses        ISSN: 0889-2229            Impact factor:   2.205


  49 in total

1.  Epidemiology of transmitted drug resistance in chronically HIV-infected patients in Germany: the RESINA study 2001-2009.

Authors:  Mark Oette; Stefan Reuter; Rolf Kaiser; Thomas Lengauer; Gerd Fätkenheuer; Heribert Knechten; Martin Hower; Herbert Pfister; Dieter Häussinger
Journal:  Intervirology       Date:  2012-01-24       Impact factor: 1.763

2.  An automated genotyping system for analysis of HIV-1 and other microbial sequences.

Authors:  Tulio de Oliveira; Koen Deforche; Sharon Cassol; Mika Salminen; Dimitris Paraskevis; Chris Seebregts; Joe Snoeck; Estrelita Janse van Rensburg; Annemarie M J Wensing; David A van de Vijver; Charles A Boucher; Ricardo Camacho; Anne-Mieke Vandamme
Journal:  Bioinformatics       Date:  2005-08-02       Impact factor: 6.937

Review 3.  Evolutionary pathways of transmitted drug-resistant HIV-1.

Authors:  Marieke Pingen; Monique Nijhuis; Johan A de Bruijn; Charles A B Boucher; Annemarie M J Wensing
Journal:  J Antimicrob Chemother       Date:  2011-04-18       Impact factor: 5.790

Review 4.  Epidemiology of antiretroviral drug resistance in drug-naïve persons.

Authors:  Anna Maria Geretti
Journal:  Curr Opin Infect Dis       Date:  2007-02       Impact factor: 4.915

5.  National sentinel surveillance of transmitted drug resistance in antiretroviral-naive chronically HIV-infected patients in France over a decade: 2001-2011.

Authors:  Diane Descamps; Lambert Assoumou; Marie-Laure Chaix; Antoine Chaillon; Sophie Pakianather; Alexis de Rougemont; Alexandre Storto; Georges Dos Santos; Anne Krivine; Constance Delaugerre; Brigitte Montes; Jacques Izopet; Charlotte Charpentier; Marc Wirden; Anne Maillard; Laurence Morand-Joubert; Coralie Pallier; Jean-Christophe Plantier; Jérôme Guinard; Catherine Tamalet; Jacqueline Cottalorda; Anne-Geneviève Marcelin; Delphine Desbois; Cecile Henquell; Vincent Calvez; Françoise Brun-Vézinet; Bernard Masquelier; Dominique Costagliola
Journal:  J Antimicrob Chemother       Date:  2013-06-24       Impact factor: 5.790

6.  Transmission of drug-resistant HIV-1 is stabilizing in Europe.

Authors:  Jurgen Vercauteren; Annemarie M J Wensing; David A M C van de Vijver; Jan Albert; Claudia Balotta; Osamah Hamouda; Claudia Kücherer; Daniel Struck; Jean-Claude Schmit; Birgitta Asjö; Marie Bruckova; Ricardo J Camacho; Bonaventura Clotet; Suzie Coughlan; Zehava Grossman; Andrzej Horban; Klaus Korn; Leondios Kostrikis; Claus Nielsen; Dimitrios Paraskevis; Mario Poljak; Elisabeth Puchhammer-Stöckl; Chiara Riva; Lidia Ruiz; Mika Salminen; Rob Schuurman; Anders Sonnerborg; Danica Stanekova; Maja Stanojevic; Anne-Mieke Vandamme; Charles A B Boucher
Journal:  J Infect Dis       Date:  2009-11-15       Impact factor: 5.226

7.  Drug resistance mutations for surveillance of transmitted HIV-1 drug-resistance: 2009 update.

Authors:  Diane E Bennett; Ricardo J Camacho; Dan Otelea; Daniel R Kuritzkes; Hervé Fleury; Mark Kiuchi; Walid Heneine; Rami Kantor; Michael R Jordan; Jonathan M Schapiro; Anne-Mieke Vandamme; Paul Sandstrom; Charles A B Boucher; David van de Vijver; Soo-Yon Rhee; Tommy F Liu; Deenan Pillay; Robert W Shafer
Journal:  PLoS One       Date:  2009-03-06       Impact factor: 3.240

8.  Persistence of transmitted drug resistance among subjects with primary human immunodeficiency virus infection.

Authors:  Susan J Little; Simon D W Frost; Joseph K Wong; Davey M Smith; Sergei L Kosakovsky Pond; Caroline C Ignacio; Neil T Parkin; Christos J Petropoulos; Douglas D Richman
Journal:  J Virol       Date:  2008-03-19       Impact factor: 5.103

9.  Changing patterns of mortality across Europe in patients infected with HIV-1. EuroSIDA Study Group.

Authors:  A Mocroft; S Vella; T L Benfield; A Chiesi; V Miller; P Gargalianos; A d'Arminio Monforte; I Yust; J N Bruun; A N Phillips; J D Lundgren
Journal:  Lancet       Date:  1998-11-28       Impact factor: 79.321

10.  High rates of transmitted drug resistance among newly-diagnosed antiretroviral naïve HIV patients in Northern Greece, data from 2009-2011.

Authors:  L Skoura; S Metallidis; D Pilalas; A Kourelis; A Margariti; E Papadimitriou; Z A Antoniadou; T Chrysanthidis; O Tsachouridou; P Kollaras; P Nikolaidis; N Malisiovas
Journal:  Clin Microbiol Infect       Date:  2013-01-17       Impact factor: 8.067

View more
  5 in total

1.  Differential regulatory activities of viral protein X for anti-viral efficacy of nucleos(t)ide reverse transcriptase inhibitors in monocyte-derived macrophages and activated CD4(+) T cells.

Authors:  Joseph A Hollenbaugh; Susan M Schader; Raymond F Schinazi; Baek Kim
Journal:  Virology       Date:  2015-08-29       Impact factor: 3.616

2.  Exploring Evolutionary and Transmission Dynamics of HIV Epidemic in Serbia: Bridging Socio-Demographic With Phylogenetic Approach.

Authors:  Luka Jovanović; Marina Šiljić; Valentina Ćirković; Dubravka Salemović; Ivana Pešić-Pavlović; Marija Todorović; Jovan Ranin; Djordje Jevtović; Maja Stanojević
Journal:  Front Microbiol       Date:  2019-02-25       Impact factor: 5.640

3.  HIV-1 transmitted drug resistance in Slovenia and its impact on predicted treatment effectiveness: 2011-2016 update.

Authors:  Maja M Lunar; Snježana Židovec Lepej; Janez Tomažič; Tomaž D Vovko; Blaž Pečavar; Gabriele Turel; Manja Maver; Mario Poljak
Journal:  PLoS One       Date:  2018-04-26       Impact factor: 3.240

Review 4.  Hemophagocytic Lymphohistiocytosis: Management and Special Consideration in Human Immunodeficiency Virus Positive Patients with Immune Reconstitution Syndrome.

Authors:  Bikramjit S Bindra; Katherine Garcia de de Jesus; Oscar Cisneros; Vinicius M Jorge; Harpreet Kaur
Journal:  Cureus       Date:  2019-08-16

5.  Analysis of HIV-1 diversity, primary drug resistance and transmission networks in Croatia.

Authors:  Maja Oroz; Josip Begovac; Ana Planinić; Filip Rokić; Maja M Lunar; Tomaž Mark Zorec; Robert Beluzić; Petra Korać; Oliver Vugrek; Mario Poljak; Snježana Židovec Lepej
Journal:  Sci Rep       Date:  2019-11-21       Impact factor: 4.379

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.